{"ok":true,"trend":{"id":1186291,"platform":"news","region":"global","key":"vital signs: adcs strike back","title":"Vital Signs: ADCs strike back","url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBlYmZrRC1ObUlpeFFQNGJxai1kYVp5TUc1Mm5jZ1J5eklBYWlNaGp5ZllaaU5NbnJHRkVZdEhDQTBhZDA4Zll3TFBTT2NfdDM2bGNV?oc=5","first_seen":"2026-10-06T03:12:18.580818Z","last_seen":"2026-10-06T14:11:23.141198Z","last_rank":34,"peak_rank":9,"last_volume":null,"peak_volume":0,"seen_count":9,"score":0.9821875,"category_hint":"labor","section":"business","category":"labor","summary":"Antibody-drug conjugates, a class of targeted cancer therapies, are reported to be striking back, suggesting renewed momentum for the technology after a period of setbacks. The item comes from FirstWord Pharma's Vital Signs series, which tracks notable developments in the pharmaceutical industry. Specific drugs, companies and clinical results behind the claim are not detailed.","why":"ADC therapies are a major focus of oncology drug development and any sign of renewed success draws close industry attention.","tone":"neutral","entities":["FirstWord Pharma","antibody-drug conjugates"],"summarized_at":"2026-10-06T15:16:32.341279Z","meta":{"via":"scan","lang":"en","term":"strike","source":"FirstWord Pharma","published":"Tue, 06 Oct 2026 02:33:37 GMT"},"nw":null,"promo":null,"kind":null,"importance":null,"hidden":false,"hide_reason":null,"judged_at":null,"title_en":"Antibody-drug conjugates regain momentum in cancer treatment","section_name":"Business","category_name":"Labor","timeline":[{"captured_at":"2026-10-06T03:12:18.580818Z","rank":10,"volume":null},{"captured_at":"2026-10-06T04:35:19.675236Z","rank":12,"volume":null},{"captured_at":"2026-10-06T05:57:19.340664Z","rank":12,"volume":null},{"captured_at":"2026-10-06T07:19:39.791952Z","rank":9,"volume":null},{"captured_at":"2026-10-06T08:41:39.069223Z","rank":11,"volume":null},{"captured_at":"2026-10-06T10:03:42.437838Z","rank":12,"volume":null},{"captured_at":"2026-10-06T11:26:21.008180Z","rank":21,"volume":null},{"captured_at":"2026-10-06T12:49:00.169313Z","rank":23,"volume":null},{"captured_at":"2026-10-06T14:11:23.141198Z","rank":34,"volume":null}],"posts":[{"platform":"news","url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBlYmZrRC1ObUlpeFFQNGJxai1kYVp5TUc1Mm5jZ1J5eklBYWlNaGp5ZllaaU5NbnJHRkVZdEhDQTBhZDA4Zll3TFBTT2NfdDM2bGNV?oc=5","author":"FirstWord Pharma","title":"Vital Signs: ADCs strike back","snippet":null,"posted_at":"2026-10-06T01:09:13Z","likes":null}],"elsewhere":[],"window":"7d"}}